Quick Reference Chart

PEDS:

0.8 mg/kg q wk (max-dose 50 mg q wk)

Humira*

Adalimumab

PsO / PsA 18 yrs +

80 mg SQ on Day 1 and then
40 mg SQ on Day 8

40 mg SQ q2 wks

TNF-α blocker

Remicade*

lnfliximab

PsO / PsA 18 yrs +

5 mg/kg IV wk 0, 2, and 6

5 mg/kg IV q8 wks

TNF-α blocker

Cimzia*

Certolizumab Pegol

PsO / PsA 18 yrs +

>90 kg: No Loading Dose

400 mg SQ q2 wks

TNF-α blocker

≤90 kg: 400 mg SQ at wk 0, 2 and 4

200 mg SQ q2 wks

Bimzelx*

Bimekizumab

PsO / PsA 18 yrs +

320 mg SQ at wk 0, 4, 8, 12, and 16

320 mg SQ q8 wks (for patients ≥ 120 kg, consider 320 mg q4 wks after wk 16)

IL-17A and F antagonist

Cosentyx*

Secukinumab

PsA 2 yrs +
PsO 6 yrs +

300 mg SQ at wk 0, 1, 2, 3, and 4

300 mg SQ q4 wks

IL-17A antagonist

PEDS:

Dosage based on body weight and administered by SQ at wks 0, 1, 2, 3, and 4 and q4 wks
Less than 50 kg = 75 mg | Greater than or equal to 50 kg = 150 mg

Taltz*

lxekizumab

PsA 18 yrs +
PsO 6 yrs +

160 mg at wk 0, then 80 mg at wk 2, 4, 6, 8, 10, and 12

80 mg SQ q4 wks

IL-17A antagonist

PEDS:

Greater than 50kg = 160 mg at wk 0 then 80 mg q4 wks | 25 to 50 kg = 80 mg at wk 0 then 40 mg q4 wks | Less than 25 kg = 40 mg at wk 0 then 20 mg q4 wks

Siliq

Brodalumab

PsO 18 yrs +

210 mg SQ at wk 0, 1, and 2

210 mg SQ q2 wks

IL-17A receptor antagonist

Stelara*

Ustekinumab

PsA 6 yrs +
PsO 6 yrs +

≤l00 kg: 45 mg SQ at wk 0 and 4

45 mg SQ q12 wks

IL-12 and IL-23 antagonist

>l00 kg: 90 mg SQ at wk 0 and 4

90 mg SQ q12 wks

PEDS:

Weight-based dosing recommended at initial dose, 4 weeks later, then q12 weeks.
Less than 60 kg = 0.75 mg/kg | 60 kg to 100 kg = 45 mg | Greater than 100 kg = 90 mg

Tremfya*

Guselkumab

PsO / PsA 18 yrs +

100 mg SQ at wk 0 and 4

100 mg SQ q8 wks

IL-23 antagonist

llumya

Tildrakizumab

PsO 18 yrs +

100 mg SQ at wk 0 and 4

100 mg SQ q12 wks

IL-23 antagonist

Skyrizi*

Risankizumab

PsO / PsA 18 yrs +

150 mg SQ at wk 0 and 4

150 mg SQ q12 wks

IL-23 antagonist

Spevigo (GPP)

Spesolimab

12 yrs + (weighing at least 40 kg)

For treatment of flare: 900 mg IV

Not experiencing a flare: 600 mg SQ

IL-36 receptor antagonist

Dupixent (Atopic Dermatitis)

Dupilumab

6 mos +

600 mg SQ (Adult Dosing)

300 mg SQ q2 wk (Adult Dosing)

IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)

PEDS 6m–5y:

5 to less than 15 kg = 200 mg SQ q4 wks | 15 to less than 30 kg = 300 mg SQ q4 wks

PEDS 6y–17y:

15 to less than 30 kg = 600 mg SQ then 300 mg q4 wks | 30 to less than 60 kg = 400 mg SQ then
200 mg q2 wks | 60 kg + = 600 mg SQ then 300 mg q2 wks

Ebglyss (Atopic Dermatitis)

Lebrikizumab

12 yrs +

500 mg (two 250-mg injections) at wk 0 and 2, then 250 mg q2 wks until 16 wks or adequate response achieved

250 mg q4 wks

IL-13 antagonist

Adbry (Atopic Dermatitis)

Tralokinumab

12 yrs +

600 mg (2 autoinjectors or 4 prefilled syringes)

300 mg q2 wks (1 autoinjector or 2 prefilled syringes); after 16 wks, q4 wks may be considered for adults <220 lbs who achieve clear or almost clear skin

IL-13 antagonist

PEDS 12y-17y:

300 mg (2 prefilled syringes)

PEDS 12y-17y:

150 mg q2 wks (1 prefilled syringe)

Nemluvio (Atopic Dermatitis)

Nemolizumab

12 yrs +

60 mg SQ (two 30-mg injections)

30 mg SQ q4 wks; for patients achieving clear or almost clear skin at 16 wks, 30 mg q8 wks recommended

IL-31 receptor antagonist